Literature DB >> 26044513

Myotonic dystrophy health index: Correlations with clinical tests and patient function.

Chad Heatwole1, Rita Bode2, Nicholas E Johnson3, Jeanne Dekdebrun1, Nuran Dilek1, Katy Eichinger1, James E Hilbert1, Eric Logigian1, Elizabeth Luebbe1, William Martens1, Michael P Mcdermott1,4, Shree Pandya1, Araya Puwanant5, Nan Rothrock6, Charles Thornton1, Barbara G Vickrey7,8, David Victorson6, Richard T Moxley1.   

Abstract

INTRODUCTION: The Myotonic Dystrophy Health Index (MDHI) is a disease-specific patient-reported outcome measure. Here, we examine the associations between the MDHI and other measures of disease burden in a cohort of individuals with myotonic dystrophy type-1 (DM1).
METHODS: We conducted a cross-sectional study of 70 patients with DM1. We examined the associations between MDHI total and subscale scores and scores from other clinical tests. Participants completed assessments of strength, myotonia, motor and respiratory function, ambulation, and body composition. Participants also provided blood samples, underwent physician evaluations, and completed other patient-reported outcome measures.
RESULTS: MDHI total and subscale scores were strongly associated with muscle strength, myotonia, motor function, and other clinical measures.
CONCLUSIONS: Patient-reported health status, as measured by the MDHI, is associated with alternative measures of clinical health. These results support the use of the MDHI as a valid tool to measure disease burden in DM1 patients.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  muscle disease; myotonic dystrophy Type-1; patient-relevant; patient-reported outcome measure; quality of life; therapeutic trial

Mesh:

Substances:

Year:  2015        PMID: 26044513      PMCID: PMC4979973          DOI: 10.1002/mus.24725

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  42 in total

1.  Reliability and feasibility of the six minute walk test in subjects with myotonic dystrophy.

Authors:  Marie Kierkegaard; Anna Tollbäck
Journal:  Neuromuscul Disord       Date:  2007-09-14       Impact factor: 4.296

2.  A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. The FSH-DY Group.

Authors: 
Journal:  Neurology       Date:  1997-01       Impact factor: 9.910

3.  Criteria for establishing the validity of genetic recombination in myotonic dystrophy.

Authors:  R C Griggs; D S Wood
Journal:  Neurology       Date:  1989-03       Impact factor: 9.910

4.  An objective and standardized test of hand function.

Authors:  R H Jebsen; N Taylor; R B Trieschmann; M J Trotter; L A Howard
Journal:  Arch Phys Med Rehabil       Date:  1969-06       Impact factor: 3.966

5.  The Lower Extremity Functional Scale (LEFS): scale development, measurement properties, and clinical application. North American Orthopaedic Rehabilitation Research Network.

Authors:  J M Binkley; P W Stratford; S A Lott; D L Riddle
Journal:  Phys Ther       Date:  1999-04

6.  Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group.

Authors:  K E Personius; S Pandya; W M King; R Tawil; M P McDermott
Journal:  Phys Ther       Date:  1994-03

7.  If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD).

Authors:  James E Hilbert; John T Kissel; Elizabeth A Luebbe; William B Martens; Michael P McDermott; Donald B Sanders; Rabi Tawil; Charles A Thornton; Richard T Moxley
Journal:  Contemp Clin Trials       Date:  2011-11-26       Impact factor: 2.226

8.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

9.  Computerized hand grip myometry reliably measures myotonia and muscle strength in myotonic dystrophy (DM1).

Authors:  Richard T Moxley; Eric L Logigian; William B Martens; Chris L Annis; Shree Pandya; Richard T Moxley; Cheryl A Barbieri; Nuran Dilek; Allen W Wiegner; Charles A Thornton
Journal:  Muscle Nerve       Date:  2007-09       Impact factor: 3.217

10.  Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history.

Authors:  M H Brooke; G M Fenichel; R C Griggs; J R Mendell; R Moxley; J P Miller; M A Province
Journal:  Muscle Nerve       Date:  1983-02       Impact factor: 3.217

View more
  11 in total

1.  Physical function and mobility in children with congenital myotonic dystrophy.

Authors:  Evan M Pucillo; Deanna L Dibella; Man Hung; Jerry Bounsanga; Becky Crockett; Melissa Dixon; Russell J Butterfield; Craig Campbell; Nicholas E Johnson
Journal:  Muscle Nerve       Date:  2017-02-13       Impact factor: 3.217

2.  [Upper abdominal pain, nausea, and vomiting in a 63-year-old woman].

Authors:  S Schwarzer; K Rapis
Journal:  Internist (Berl)       Date:  2017-12       Impact factor: 0.743

Review 3.  Drug Development and Challenges for Neuromuscular Clinical Trials.

Authors:  Mohamed El Mouelhi
Journal:  J Mol Neurosci       Date:  2015-12-21       Impact factor: 3.444

4.  Brief assessment of cognitive function in myotonic dystrophy: Multicenter longitudinal study using computer-assisted evaluation.

Authors:  Gayle K Deutsch; Katharine A Hagerman; Jacinda Sampson; Gersham Dent; Jeanne Dekdebrun; Dana M Parker; Charles A Thornton; Chad R Heatwole; Sub H Subramony; Ami K Mankodi; Tetsuo Ashizawa; Jeffrey M Statland; W David Arnold; Richard T Moxley; John W Day
Journal:  Muscle Nerve       Date:  2022-02-28       Impact factor: 3.852

5.  Encoding of facial expressions in individuals with adult-onset myotonic dystrophy type 1.

Authors:  Claire Johnson; Kathleen E Langbehn; Jeffrey D Long; David Moser; Stephen Cross; Laurie Gutmann; Peggy C Nopoulos; Ellen van der Plas
Journal:  J Clin Exp Neuropsychol       Date:  2020-10-07       Impact factor: 2.475

6.  Patient-identified impact of symptoms in spinal and bulbar muscular atrophy.

Authors:  Robert D Guber; Angela D Kokkinis; Alice B Schindler; Roxanna M Bendixen; Chad R Heatwole; Kenneth H Fischbeck; Christopher Grunseich
Journal:  Muscle Nerve       Date:  2017-09-25       Impact factor: 3.217

7.  Analysis of the functional capacity outcome measures for myotonic dystrophy.

Authors:  Aura Cecilia Jimenez-Moreno; Nikoletta Nikolenko; Marie Kierkegaard; Alasdair P Blain; Jane Newman; Charlotte Massey; Dionne Moat; Jas Sodhi; Antonio Atalaia; Grainne S Gorman; Chris Turner; Hanns Lochmüller
Journal:  Ann Clin Transl Neurol       Date:  2019-07-22       Impact factor: 4.511

8.  White matter microstructure relates to motor outcomes in myotonic dystrophy type 1 independently of disease duration and genetic burden.

Authors:  Timothy R Koscik; Ellen van der Plas; Laurie Gutmann; Sarah A Cumming; Darren G Monckton; Vincent Magnotta; Richard K Shields; Peggy C Nopoulos
Journal:  Sci Rep       Date:  2021-03-01       Impact factor: 4.379

9.  Outcome Measures for Central Nervous System Evaluation in Myotonic Dystrophy Type 1 May Be Confounded by Deficits in Motor Function or Insight.

Authors:  Mark J Hamilton; John McLean; Sarah Cumming; Bob Ballantyne; Josephine McGhie; Ravi Jampana; Cheryl Longman; Jonathan J Evans; Darren G Monckton; Maria Elena Farrugia
Journal:  Front Neurol       Date:  2018-10-02       Impact factor: 4.003

10.  Clinical Outcome Evaluations and CBT Response Prediction in Myotonic Dystrophy.

Authors:  Daniël van As; Kees Okkersen; Guillaume Bassez; Benedikt Schoser; Hanns Lochmüller; Jeffrey C Glennon; Hans Knoop; Baziel G M van Engelen; Peter A C 't Hoen
Journal:  J Neuromuscul Dis       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.